Have Insiders Sold Jounce Therapeutics, Inc. (NASDAQ:JNCE) Shares Recently?

Anyone interested in Jounce Therapeutics, Inc. (NASDAQ:JNCE) should probably be aware that the President, Richard Murray, recently divested US$152k worth of shares in the company, at an average price of US$6.89 each. That sale was 14% of their holding, so it does make us raise an eyebrow.

View our latest analysis for Jounce Therapeutics

The Last 12 Months Of Insider Transactions At Jounce Therapeutics

In fact, the recent sale by Richard Murray was the biggest sale of Jounce Therapeutics shares made by an insider individual in the last twelve months, according to our records. So it's clear an insider wanted to take some cash off the table, even below the current price of US$7.20. When an insider sells below the current price, it suggests that they considered that lower price to be fair. That makes us wonder what they think of the (higher) recent valuation. While insider selling is not a positive sign, we can't be sure if it does mean insiders think the shares are fully valued, so it's only a weak sign. It is worth noting that this sale was only 14% of Richard Murray's holding.

Insiders in Jounce Therapeutics didn't buy any shares in the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

I will like Jounce Therapeutics better if I see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

Does Jounce Therapeutics Boast High Insider Ownership?

For a common shareholder, it is worth checking how many shares are held by company insiders. We usually like to see fairly high levels of insider ownership. Our data suggests Jounce Therapeutics insiders own 1.3% of the company, worth about US$3.8m. I generally like to see higher levels of ownership.

What Might The Insider Transactions At Jounce Therapeutics Tell Us?

Insiders haven't bought Jounce Therapeutics stock in the last three months, but there was some selling. And even if we look at the last year, we didn't see any purchases. When you consider that most companies have higher levels of insider ownership, we're a little wary. We'd certainly practice some caution before buying! So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. To that end, you should learn about the 5 warning signs we've spotted with Jounce Therapeutics (including 1 which doesn't sit too well with us).

Of course Jounce Therapeutics may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

When trading Jounce Therapeutics or any other investment, use the platform considered by many to be the Professional's Gateway to the Worlds Market, Interactive Brokers. You get the lowest-cost* trading on stocks, options, futures, forex, bonds and funds worldwide from a single integrated account. Promoted

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
^*Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.